share_log

HC Wainwright & Co. Maintains Buy on Relay Therapeutics, Lowers Price Target to $18

HC Wainwright & Co. Maintains Buy on Relay Therapeutics, Lowers Price Target to $18

HC Wainwright & Co.維持對Relay Therapeutics的買入評級,將目標股價下調至18美元。
Benzinga ·  07/17 06:22

HC Wainwright & Co. analyst Robert Burns maintains Relay Therapeutics (NASDAQ:RLAY) with a Buy and lowers the price target from $20 to $18.

HC Wainwright & Co.分析師Robert Burns 維持Buy評級,將Relay Therapeutics(納斯達克代碼:RLAY)的目標價從$20降至$18。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論